{"version":"1.0","type":"link","title":"OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer.","author_name":"Xu B 외","author_url":"https://prs-insight.online/author/Xu%20B","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/81043","thumbnail_width":1200,"thumbnail_height":630}